Sunshine Biopharma, Inc.
NASDAQ Capital MarketTotal Valuation
Sunshine Biopharma, Inc. carries a market capitalization of 906,070.00, placing it among publicly traded companies globally. Its enterprise value stands at -1.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 906,070.00 |
| Enterprise Value | -1.32M |
Share Statistics
Sunshine Biopharma, Inc. currently has 490,594.00 shares outstanding.
| Shares Outstanding | 490,594.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.14, and the price-to-book ratio stands at -0.06.
| PE Ratio | N/A |
| PS Ratio | 0.14 |
| PB Ratio | -0.06 |
| P/TBV Ratio | 0.25 |
| P/FCF Ratio | -0.97 |
| P/OCF Ratio | -0.85 |
Enterprise Valuation
| EV / Sales | 4.38 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Sunshine Biopharma, Inc. maintains a current ratio of 4.22, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.22 |
| Quick Ratio | 1.86 |
| Debt / Equity | 3.46 |
| Debt / EBITDA | -0.18 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -21.15 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.90 |
Taxes
| Income Tax | 61,770.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Sunshine Biopharma, Inc.'s stock has declined approximately -88.61635% over the past 52 weeks. The 50-day moving average sits at 3.16, while the 200-day moving average is 10.70.
| Beta (5Y) | N/A |
| 52-Week Price Change | -88.61635% |
| 50-Day Moving Average | 3.16 |
| 200-Day Moving Average | 10.70 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Sunshine Biopharma, Inc. generated 35.49M in revenue and converted that into -6.04M in net income, yielding earnings per share of -12.98. EBITDA reached -4.23M, while operating income came in at -4.58M.
| Revenue | 35.49M |
| Gross Profit | 11.71M |
| Operating Income | -4.58M |
| Pretax Income | -5.98M |
| Net Income | -6.04M |
| EBITDA | -4.23M |
| EBIT | -4.58M |
| Earnings Per Share (EPS) | -12.98 |
Balance Sheet
Sunshine Biopharma, Inc. holds 6.91M in cash and equivalents against 744,840.00 in total debt, resulting in a net debt position of -6.91M. Total book value stands at -76.25M, with working capital of 18.91M providing operational flexibility.
| Cash & Cash Equivalents | 6.91M |
| Total Debt | 744,840.00 |
| Net Debt | -6.91M |
| Equity (Book Value) | -76.25M |
| Book Value Per Share | -163.89 |
| Working Capital | 18.91M |
Cash Flow
Sunshine Biopharma, Inc. produced -5.71M in operating cash flow over the past twelve months. After subtracting -728,807.00 in capital expenditures, free cash flow totaled -6.44M - equivalent to -13.84 per share.
| Operating Cash Flow | -5.71M |
| Capital Expenditures | -728,807.00 |
| Free Cash Flow | -6.44M |
| FCF Per Share | -13.84 |
Margins
Sunshine Biopharma, Inc. operates with a gross margin of 32.98, reflecting its pricing power and cost economics. The operating margin of -12.90 and net profit margin of -17.02 provide insight into operational efficiency.
| Gross Margin | 32.98 |
| Operating Margin | -12.90 |
| Pretax Margin | -16.84 |
| Profit Margin | -17.02 |
| EBITDA Margin | -11.93 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -90.79 |
| FCF Yield | -102.91 |
Stock Splits
Sunshine Biopharma, Inc.'s most recent stock split took place on June 1, 2026 with a 10:1 split ratio.
| Last Split Date | 6/1/2026 |
| Split Ratio | 10:1 |
Scores
Sunshine Biopharma, Inc. posts an Altman Z-Score of -2.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.00 |